| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The novel essence of this study lies in the finding that dedifferentiated Schwann cell-derived galectin-3 plays a pro-nociceptive role via macrophage infiltration in the pathogenesis of taxane-induced peripheral neuropathy.
On the other hand, we demonstrated here that a phosphodiesterase 3 inhibitor, cilostazol, strongly facilitates maturation of primary cultures of rat Schwann cells . Co-treatment with cilostazol prevented paclitaxel-induced dedifferentiation of Schwann cell cultures and demyelination in a mixed culture of Schwann cells and DRG neurons. Notably, consecutive oral administration of cilostazol (0.3% in chow diets) suppressed Schwann cell dedifferentiation within the sciatic nerve and the development of mechanical hypersensitivity in CIPN model mice generated by multiple intraperitoneal injections of paclitaxel.
|
